Soleno Therapeutics (SLNO) Other Non Operating Income (2013 - 2023)

Soleno Therapeutics (SLNO) has 11 years of Other Non Operating Income data on file, last reported at $2.1 million in Q4 2023.

• On a quarterly basis, Other Non Operating Income rose 1615.2% year-over-year to $2.1 million in Q4 2023; TTM through Dec 2023 was $2.6 million, a 759.33% increase from a year earlier, with the FY2023 full-year figure at $2.6 million, up 759.33% from the prior year.
• Other Non Operating Income for Q4 2023 stood at $2.1 million, up from $174000.0 in the prior quarter.
• Over the last five years, Other Non Operating Income for SLNO reached as high as $2.1 million in Q4 2023 and fell as low as $1000.0 in Q2 2020.
• Historically, Other Non Operating Income has averaged $166052.6 across 5 years, with a median of $41000.0 in 2021.
• Across the five-year window, Other Non Operating Income slumped 97.87% in 2020 and surged 4000.0% in 2021, its largest moves.
• Year by year, Other Non Operating Income stood at $21000.0 in 2019, then slumped by 95.24% to $1000.0 in 2020, then surged by 3300.0% to $34000.0 in 2021, then surged by 267.65% to $125000.0 in 2022, then jumped by 1615.2% to $2.1 million in 2023.
• Per Business Quant data, the three most recent Other Non Operating Income figures were $2.1 million in Q4 2023, $174000.0 in Q3 2023, and $147000.0 in Q2 2023.